免疫检查点抑制剂在乳头状肾细胞癌中是否有效?多中心回顾性研究
该多中心回顾性研究纳入57例转移性乳头状肾细胞癌患者,评估PD-1/PD-L1抑制剂单药治疗的活性。中位随访12个月,中位至治疗失败时间3.1个月,客观缓解率11%,中位总生存14.6个月,III-IV级治疗相关不良事件发生率10%。结论认为PD-1/PD-L1抑制剂单药活性有限,仍需前瞻性联合治疗试验。
要点
- PD-1/PD-L1抑制剂单药在转移性乳头状肾细胞癌中客观缓解率仅11%。
- 中位至治疗失败时间3.1个月,中位总生存14.6个月。
- III-IV级治疗相关不良事件发生率10%,无V级不良事件。
核心结论
- PD-1/PD-L1抑制剂单药在转移性乳头状肾细胞癌中活性有限,仍为未满足的临床需求。
- 研究提示需进一步开展评估免疫检查点抑制剂联合方案的前瞻性临床试验。
研究设计与样本
- 多中心回顾性研究,纳入2016年2月至2019年1月共57例乳头状肾细胞癌患者。
- 组织学类型包括1型16例(28%)、2型34例(60%)和未分类7例(12%)。
- 免疫检查点抑制剂用于一线4例(7%)、二线32例(56%)、三线及以上21例(37%)。
- 主要终点为至治疗失败时间(TTF),次要终点包括客观缓解率(ORR)、总生存(OS)和治疗相关不良事件(TRAEs)。
主要发现
- 中位随访12个月(95%CI:9.9-21.0),中位TTF为3.1个月(95%CI:2.7-5.0)。
- 55例可评估ORR的患者中,完全缓解/部分缓解6例(11%),疾病稳定18例(33%),疾病进展31例(56%)。
- 中位OS为14.6个月(95%CI:9.0-未达到)。
- III-IV级TRAEs见于6例(10%),导致治疗中断,未观察到V级TRAEs。
临床怎么用
- PD-1/PD-L1抑制剂单药在转移性乳头状肾细胞癌中获益有限,临床决策需权衡疗效与毒性。
- 对于乳头状肾细胞癌患者,可考虑参加评估免疫检查点抑制剂联合方案的前瞻性临床试验。
局限性
- 回顾性研究设计,样本量较小(57例),可能存在选择偏倚。
- 免疫检查点抑制剂使用线数不一(一线至三线及以上),异质性较大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Papillary renal cell carcinoma (pRCC) is the most common non-clear cell RCC (nccRCC). Pivotal studies evaluating immune checkpoint inhibitors mostly excluded nccRCC. The aim of this retrospective and multicentre study was to evaluate the activity of programmed death-1 (PD-1)/ programmed death-ligand 1 (PD-L1) inhibitors specifically in metastatic pRCC. METHODS: The primary end-point was time to treatment failure (TTF). Secondary endpoints included objective response rate (ORR), overall survival (OS) and treatment-related adverse events (TRAEs). RESULTS: From 02/2016 to 01/2019, 57 patients with pRCC were included. Histology included 16 (28%) type 1 pRCC, 34 (60%) type 2 pRCC and 7 (12%) unclassified pRCC. Treatment with immune checkpoint inhibitors was used in the first-line setting in 4 patients (7%), in the second-line setting in 32 patients (56%) and in the third-line setting or more in 21 patients (37%). With a median follow-up of 12 months (95% confidence interval [CI]: 9.9-21.0), the median TTF was 3.1 months (95% CI: 2.7-5.0). Among the 55 patients evaluable for ORR, best response was complete response/partial response in 6 patients (11%), stable disease in 18 patients (33%) and progressive disease in 31 patients (56%). The median OS was 14.6 months (95% CI: 9.0- not reached). TRAEs of grade III-IV were noted in 6 patients (10%) leading to treatment discontinuation, and no grade V TRAEs were observed. CONCLUSION: PD-1/PD-L1 inhibitors exhibit limited activity as monotherapy in this pRCC population, which remains an unmet need. Our findings underline the need for further prospective clinical trials evaluating immune checkpoint inhibitor combinations in patients with pRCC.
引用
- de Vries-Brilland M, Gross-Goupil M, Seegers V, et al. Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study. Eur J Cancer. 2020. PMID: 32653774. doi:10.1016/j.ejca.2020.02.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。